Product Details
1/EA
$ *.**
In StockAdditional Information
| Product Name | Ruxience 500 Mg/50 Ml Vial |
| Active Ingredient | Rituximab-pvvr (biosimilar) |
| Mechanism of Action | Binds to CD20 on B cells, leading to B-cell depletion via cytotoxic and apoptotic pathways |
| Strength | 500 mg / 50 mL (10 mg/mL) |
| Route of Administration | Intravenous infusion |
| Common Side Effects | Infusion reactions, fever, chills, nausea, fatigue, rash |
| Serious Adverse Effects | Progressive multifocal leukoencephalopathy (PML), severe infections, tumor lysis syndrome, cardiac events |
| Precautions | Premedication required, screen for hepatitis B, monitor for delayed adverse effects |
| Storage Conditions | Refrigerate at 2°C to 8°C (36°F to 46°F), protect from light, do not freeze or shake |
| Packaging | 50 mL single-use vial |
| Uses | Non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA) |
Description
Ruxience 500 mg/50 mL vial is a biosimilar of rituximab, a monoclonal antibody targeting the CD20 antigen on B lymphocytes. It is indicated for the treatment of non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), rheumatoid arthritis (RA), granulomatosis with polyangiitis (GPA), and microscopic polyangiitis (MPA). By depleting CD20-positive B cells, Ruxience reduces malignant cell proliferation in hematologic malignancies and modulates immune responses in autoimmune diseases.
The mechanism of action involves binding to the CD20 antigen on the surface of B cells, leading to cell death through complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and direct apoptosis. This targeted B-cell depletion reduces disease activity in autoimmune disorders and improves survival rates in B-cell malignancies.
Infusion reactions, including fever, chills, hypotension, and bronchospasm, are common, particularly during the first infusion. Premedication with antihistamines, corticosteroids, and acetaminophen is recommended to minimize these effects. Serious adverse events include progressive multifocal leukoencephalopathy (PML), severe infections, tumor lysis syndrome, and cardiac complications.
Frequently Asked Questions (FAQs)
The cost of Ruxience 500 Mg/50 ML Vial is $$0.00
Ruxience 500 Mg/50 ML Vial is manufactured by Pfizer.
You can purchase Ruxience 500 Mg/50 ML Vial on our website at https://supplies.pipelinemedical.com/product/detail/ruxience-sf-10mg-ml-50ml-651323